← Back to Search

Brain Stimulation

Brain Stimulation for Schizophrenia

N/A
Recruiting
Research Sponsored by University of California, Davis
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessment will begin immediately following stimulation and last for about 1.5 hours.

Summary

This trial is studying how well transcranial direct current stimulation (tDCS) works in improving higher-order cognition in people with and without schizophrenia.

Who is the study for?
This trial is for adults with schizophrenia, schizophreniform or schizoaffective disorder who have stable mental health, no recent medication changes, and a normal IQ. They must not be on clozapine, pregnant, have uncorrected vision issues that affect testing or skin conditions at electrode sites. Participants should not have substance abuse history in the last month or metal implants.
What is being tested?
The study tests how brain function related to higher-order cognition (like language comprehension and memory) is affected by transcranial direct current stimulation (tDCS). It compares the effects of tDCS on different brain regions using behavioral tasks and EEG monitoring in both healthy individuals and those with schizophrenia.
What are the potential side effects?
Potential side effects from tDCS may include discomfort at the electrode site, itching, tingling during application, headache after treatment sessions, fatigue or nausea. Serious risks are rare but can include seizures or skin burns.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessment will begin immediately following stimulation and last for about 1.5 hours.
This trial's timeline: 3 weeks for screening, Varies for treatment, and assessment will begin immediately following stimulation and last for about 1.5 hours. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Behavioral Response (Cognitive Control Task)
Behavioral Response (Language Task)
EEG Correlates of Language and Cognitive Control

Side effects data

From 2021 Phase 2 & 3 trial • 160 Patients • NCT02483468
2%
skin irritation
2%
Car accident
100%
80%
60%
40%
20%
0%
Study treatment Arm
tDCS (Active)
tDCS (Sham)

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: DLPFC StimulationExperimental Treatment1 Intervention
Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex.
Group II: Occipital StimulationActive Control1 Intervention
Intervention. 20 minutes of 2 mA direct current stimulation over the occipital cortex.
Group III: Sham StimulationPlacebo Group1 Intervention
Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Direct Current Stimulation
2014
Completed Phase 3
~1100

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor
946 Previous Clinical Trials
4,756,010 Total Patients Enrolled
3 Trials studying Schizophrenia
171 Patients Enrolled for Schizophrenia

Media Library

Transcranial Direct Current Stimulation (Brain Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT03814967 — N/A
Schizophrenia Research Study Groups: Sham Stimulation, DLPFC Stimulation, Occipital Stimulation
Schizophrenia Clinical Trial 2023: Transcranial Direct Current Stimulation Highlights & Side Effects. Trial Name: NCT03814967 — N/A
Transcranial Direct Current Stimulation (Brain Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03814967 — N/A
~2 spots leftby Jan 2025